Business & regional news

Findings highlight the potential of new investigational waveforms for the all-in-one mapping and dual-energy ablation system in advancing treatment for ventricular arrhythmia patients

New investigational energy waveforms created specifically to target ventricular arrhythmias

Ventricular arrhythmia research will provide important clinical evidence using a new technology for patient population in need of new treatment options

Data include durability of PulseSelect integrated with the Affera system, same day discharge and zero fluoroscopy with Affera and Sphere-9™ Catheter

Highlights underscore positive momentum of commercial launch of Affera in the U.S. and continued strong adoption of PulseSelect globally

Real-world use continues to demonstrate safety, efficacy and efficiency of both PFA technologies amid global expansion

The VT research will provide important clinical evidence in an underserved patient population

Post-market data collection will add real-world experience to established safety, efficacy, and efficiency evidence profile

Physician feedback confirms clinical evidence: safe, efficient, and effective treatment offers most versatile new option for atrial fibrillation

Simplicity, efficiency, efficacy with unmatched safety data to set a new standard in catheter ablation

Heart Rhythm 2023: Late-breaking analysis of the PULSED AF Trial reveals first of its kind significant, meaningful quality of life improvements and healthcare utilization benefits of the PulseSelect Pulsed Field Ablation System

12-month results reinforce versatility and durability for the treatment of paroxysmal and persistent AFib with the first-of-its-kind pulsed field ablation, radiofrequency, and high density mapping Sphere-9™ Catheter